CurtisRChongMD

Oncology • Palo Alto, CA

Clinical Fellow in Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Chong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chong's full profile

Already have an account?

Office
300 Pasteur Dr
Palo Alto, CA 94304
Phone+1 650-723-4000

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
Johns Hopkins University School of MedicineClass of 2008

Certifications & Licensure

MA State Medical License 2010 - 2026
CA State Medical License 2016 - 2025
NY State Medical License 2016 - 2020
NJ State Medical License 2017 - 2019
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

727 citations
New uses for old drugs
Curtis R. Chong, David J. Sullivan
Nature. 2007-08-09
92 citations
Reading dynamic kinase activity in living cells for high-throughput screening.
Michael D. Allen, Lisa M. DiPilato, Meghdad Rahdar, Yunzhao R. Ren, Curtis R. Chong
ACS Chemical Biology. 2006-07-21
761 citations
The quest to overcome resistance to EGFR-targeted therapies in cancer
Curtis R. Chong, Pasi A. Jänne
Nature Medicine. 2013-11-01

Lectures

A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

مضادات الفيروسات التي لم تكن يوما كذلك: نتائج مضللة كانت نِتاج إعادة توجيه أدوية مُرخصة لمعالجة الكوفيد 19July 11th, 2021